FDA Advisers Consider Novavax COVID-19 Vaccine This Week
An FDA panel will consider Novavaxs COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.
New Zealand United Kingdom South Korea Novavax Covid Stanley Erck Products Advisory Committee Meeting
Source: medscape.com